Edition:
United States

Acorda Therapeutics Inc (ACOR.OQ)

ACOR.OQ on NASDAQ Stock Exchange Global Select Market

18.99USD
12:10pm EST
Change (% chg)

$0.02 (+0.11%)
Prev Close
$18.97
Open
$18.86
Day's High
$19.42
Day's Low
$18.68
Volume
41,893
Avg. Vol
228,572
52-wk High
$36.25
52-wk Low
$15.65

Latest Key Developments (Source: Significant Developments)

Grünenthal Acquires Global Rights For Qutenza
Monday, 5 Nov 2018 08:15am EST 

Nov 5 (Reuters) - Acorda Therapeutics Inc ::GRÜNENTHAL ACQUIRES GLOBAL RIGHTS FOR QUTENZA®.GRÜNENTHAL GROUP - ACQUIRED ADDITIONAL GLOBAL COMMERCIAL RIGHTS FOR DERMAL PAIN PATCH QUTENZA (8% CAPSAICIN) FROM ACORDA THERAPEUTICS.  Full Article

Acorda Therapeutics Q3 GAAP Loss Per Share Of $0.29
Wednesday, 31 Oct 2018 06:00am EDT 

Oct 31 (Reuters) - Acorda Therapeutics Inc ::ACORDA PROVIDES FINANCIAL AND PIPELINE UPDATE FOR THIRD QUARTER 2018.Q3 REVENUE $142.8 MILLION .Q3 GAAP LOSS PER SHARE $0.29.Q3 NON-GAAP EARNINGS PER SHARE $0.17.Q3 EARNINGS PER SHARE VIEW $-0.02 -- THOMSON REUTERS I/B/E/S.Q3 REVENUE VIEW $82.8 MILLION -- THOMSON REUTERS I/B/E/S.2018 NET REVENUE GUIDANCE INCREASED FROM $330-$350 MILLION TO MORE THAN $400 MILLION.CASH BALANCE FOR YEAR-END 2018 REVISED FROM MORE THAN $300 MILLION TO MORE THAN $400 MILLION.ACORDA THERAPEUTICS - AT SEPT 30, CO HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $460.9 MILLION.SEES AMPYRA 2018 NET REVENUE MORE THAN $400 MILLION.ACORDA THERAPEUTICS - SEES 2018 RESEARCH AND DEVELOPMENT EXPENSES TO BE $100-$110 MILLION INCLUDING PRE-LAUNCH MANUFACTURING EXPENSES ASSOCIATED WITH INBRIJA.  Full Article

Acorda Provides Financial And Pipeline Update For Q3 2018
Wednesday, 31 Oct 2018 06:00am EDT 

Oct 31 (Reuters) - Acorda Therapeutics Inc ::ACORDA PROVIDES FINANCIAL AND PIPELINE UPDATE FOR THIRD QUARTER 2018.Q3 GAAP LOSS PER SHARE $0.29.Q3 NON-GAAP EARNINGS PER SHARE $0.17.Q3 REVENUE $138 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.02 -- THOMSON REUTERS I/B/E/S.Q3 REVENUE VIEW $82.8 MILLION -- THOMSON REUTERS I/B/E/S.2018 NET REVENUE GUIDANCE INCREASED FROM $330-$350 MILLION TO MORE THAN $400 MILLION.CASH BALANCE FOR YEAR-END 2018 REVISED FROM MORE THAN $300 MILLION TO MORE THAN $400 MILLION.ACORDA THERAPEUTICS - AT SEPT 30, CO HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $460.9 MILLION.SEES AMPYRA 2018 NET REVENUE MORE THAN $400 MILLION.ACORDA THERAPEUTICS - SEES 2018 RESEARCH AND DEVELOPMENT EXPENSES TO BE $100-$110 MILLION INCLUDING PRE-LAUNCH MANUFACTURING EXPENSES ASSOCIATED WITH INBRIJA.  Full Article

Acorda Therapeutics Announces U.S. Federal Court Upholds Decision To Invalidate Ampyra Patents
Monday, 10 Sep 2018 11:47am EDT 

Sept 10 (Reuters) - Acorda Therapeutics Inc ::U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT UPHOLDS DISTRICT COURT’S DECISION TO INVALIDATE AMPYRA® (DALFAMPRIDINE) PATENTS.ACORDA THERAPEUTICS - U.S. COURT OF APPEALS FOR FEDERAL CIRCUIT, BY A 2-1 VOTE, HAS UPHELD U.S. COURT'S DECISION TO INVALIDATE FOUR AMPYRA PATENTS.  Full Article

Acorda Announces FDA Acceptance Of New Drug Application For Inbrija
Tuesday, 20 Feb 2018 06:00am EST 

Feb 20 (Reuters) - Acorda Therapeutics Inc ::ACORDA ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR INBRIJA™ (LEVODOPA INHALATION POWDER).ACORDA THERAPEUTICS INC - UNDER PRESCRIPTION DRUG USER FEE ACT (PDUFA), FDA HAS SET A TARGET DATE OF OCTOBER 5, 2018 FOR INBRIJA.  Full Article

Acorda Therapeutics Q4 Adj Shr $0.61
Thursday, 15 Feb 2018 06:00am EST 

Feb 15 (Reuters) - Acorda Therapeutics Inc ::Q4 REVENUE $188.4 MILLION.Q4 NON-GAAP EARNINGS PER SHARE $0.61.Q4 GAAP LOSS PER SHARE $3.70.AMPYRA NET REVENUE IS EXPECTED TO BE $330 MILLION TO $350 MILLION IN 2018.RESEARCH AND DEVELOPMENT EXPENSES FOR FULL YEAR 2018 ARE EXPECTED TO BE $100 MILLION TO $110 MILLION.  Full Article

Acorda Therapeutics Sees FY 2018 Sales $330 Mln To $350 Mln For AMPYRA
Monday, 8 Jan 2018 07:00am EST 

Jan 8 (Reuters) - Acorda Therapeutics Inc ::ACORDA ANNOUNCES 2017 AMPYRA NET SALES AND PROVIDES 2018 FINANCIAL GUIDANCE AT J.P. MORGAN HEALTHCARE CONFERENCE.SEES FY 2018 SALES $330 MILLION TO $350 MILLION FOR AMPYRA.INBRIJA NDA RESUBMITTED IN DECEMBER 2017; INITIAL FDA RESPONSE EXPECTED IN FEBRUARY 2018.YEAR-END CASH BALANCE FOR 2018 IS PROJECTED TO BE OVER $300 MILLION.  Full Article

Acorda Therapeutics Is Exploring A Potential Sale - WSJ, Citing Sources
Friday, 5 Jan 2018 03:39pm EST 

Jan 5 (Reuters) - Acorda Therapeutics Inc ::ACORDA THERAPEUTICS IS EXPLORING A POTENTIAL SALE - WSJ, CITING SOURCES.  Full Article

Acorda Resubmits New Drug Application For INBRIJA
Thursday, 7 Dec 2017 06:00am EST 

Dec 7 (Reuters) - Acorda Therapeutics Inc ::ACORDA RESUBMITS NEW DRUG APPLICATION FOR INBRIJA™ (CVT-301, LEVODOPA INHALATION POWDER).SAYS RESUBMISSION ADDRESSED TWO ISSUES RAISED IN RECENT REFUSAL TO FILE (RTF) LETTER.SAYS RESUBMISSION ALSO INCLUDED ALL ADDITIONAL INFORMATION REQUESTED BY FDA IN ITS LETTER.SAYS INBRIJA NDA IS BEING SUBMITTED AS A 505(B)(2) APPLICATION.  Full Article

Acorda discontinues Tozadenant development program
Monday, 20 Nov 2017 07:00am EST 

Nov 20 (Reuters) - Acorda Therapeutics Inc ::Acorda discontinues tozadenant development program.Says also ‍immediately discontinuing dosing of all participants currently enrolled in its tozadenant studies​.Acorda Therapeutics - ‍decision based on new information obtained from phase 3 program related to previously disclosed agranulocytosis and associated serious adverse events​.Acorda Therapeutics - concluded that it could not be confident that weekly white blood cell count screening would sufficiently ensure patient safety​.Says it ‍has informed regulatory authorities and trial investigators regarding orderly closure of ongoing studies​.Acorda Therapeutics - ‍over 90 percent of participants in placebo-controlled phase 3 efficacy and safety study, cl-05, have completed study​.Acorda Therapeutics - ‍expects data from the participants in q1 of 2018 and to present these at appropriate medical/scientific venues​.  Full Article

U.S. appeals court invalidates Acorda patents on MS drug

A U.S. appeals court on Monday invalidated Acorda Therapeutics Inc patents covering its multiple sclerosis drug Ampyra, opening the door to generic competition for the company's flagship product.